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The China Assessment of Antifungal Therapy in Hematological Disease study, the ﬁrst large-scale observa-
tional study of invasive fungal disease (IFD) in China, enrolled 1401 patients undergoing hematopoietic stem
cell transplantation (HSCT) (75.2% allogeneic and 24.8% autologous) at 31 hospitals across China. The overall
incidence of proven or probable IFD was 7.7% (108 of 1401); another 266 cases (19.0%) were possible IFD. After
allogeneic or autologous HSCT, the incidence of proven/probable IFD was 8.9% (94 of 1053) and 4.0% (14 of
348), respectively. Some cases (14 of 108) developed during conditioning before transplantation. The cu-
mulative incidence of proven/probable IFD increased steeply in the ﬁrst month after transplantation and after
6 months, the incidence was signiﬁcantly higher in allogeneic than it was in autologous transplant recipients
(9.2% versus 3.5%; P ¼ .001) and when stem cells were derived from cord blood or bone marrow and pe-
ripheral blood (P ¼ .02 versus other sources). Independent risk factors for proven/probable IFD in allogeneic
HSCT were diabetes, HLA-matched unrelated donor, prolonged severe neutropenia (absolute neutrophil count
> 500/mm3 for >14 days), and immunosuppressants (odds ratio, 2.0 to 3.4 for all). Antifungal prophylaxis was
independently protective (P ¼ .01). Previous IFD and prolonged severe neutropenia were signiﬁcant inde-
pendent risk factors among autologous transplantation patients (P < .01, P ¼ .04, respectively). In total, 1175
(83.9%) patients received antifungal prophylaxis (91.6% triazoles) and 514 (36.7%) were treated in the hospital
with therapeutic antifungals (89.1% triazoles; median 27 days). Empirical, pre-emptive, and targeted anti-
fungals were used in 82.3%, 13.6%, and 4.1% of cases, respectively. Overall mortality (13.4%; 188 deaths) was
markedly higher in patients with proven (5 of 16; 31.3%), probable (20 of 92; 21.7%), or possible (61 of 266;
22.9%) IFD; allogeneic (171 of 1053; 16.2%) rather than autologous (17 of 348; 4.9%) HSCT and was signiﬁcantly
higher in patients receiving pre-emptive (18.6%) rather than empirical (6.1%) or targeted (9.5%) antifungal
therapy (P ¼ .002). Improvements in the selection and timing of prophylactic antifungals would be welcome.
Health care providers should remain alert to the increased risk of IFD and associated mortality in allogeneic
HSCT recipients and the ongoing risk of IFD even after discharge from the hospital.
 2015 American Society for Blood and Marrow Transplantation.dgments on page 1125.
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Invasive fungal disease (IFD) is a common complication
after hematopoietic stem cell transplantation (HSCT) and is
associated with signiﬁcant morbidity and mortality [1]. Until
recently, the epidemiology of IFD in HSCT was gleaned pri-
marily from single-center and retrospective studies. How-
ever, the publication of large, prospective observational
studies in recent years has improved understanding of the
epidemiological landscape in geographical areas including
the United States and parts of Europe [2-4]. These data
suggest that, despite reductions in IFD-related deaths in the
past decade [5], IFD-related mortality after HSCT still ap-
proaches 50% [2,3], with higher rates among recipients of
allogeneic compared with autologous transplants, particu-
larly in the presence of Aspergillus infection [2,4]. As a result,
HSCT recipients with suspected IFD often receive early
empirical therapy or pre-emptive treatment.
Treatment guidelines for IFD, including some that are
speciﬁc to HSCT patients, have been developed by academic
societies in different world regions [6-9]. Notwithstanding
this guidance, and despite advances in the diagnosis and
prophylaxis of IFD, as well as new dose forms of amphoter-
icin B and antifungal agents, treatment is often delayed
because of nonspeciﬁc disease presentation and a lack of
reliable diagnostic techniques, leading to poor clinical
outcomes.
Data on the epidemiology and real-world management of
IFD in high-risk patients in China are limited to a small
number of single-center retrospective studies. Here, we
report ﬁndings from the China Assessment of Antifungal
Therapy in Hematological Disease (CAESAR) study, the ﬁrst
large-scale observational study of the epidemiology, risk
factors, management and prognosis of IFD among adults and
children undergoing HSCT in China.METHODS
Study Design
The CAESAR study was a multicenter, prospective, observational study
in 35 hematology centers across China, including 2 children’s hospitals.
Subjects were consecutive patients of any age with hematological malig-
nancy who were hospitalized during the study period either after allogeneic
or autologous HSCT or to receive intravenous chemotherapy. Overall study
methods have been described previously [10]. This report focuses on pa-
tients who underwent HSCT in 31 HSCT centers; data from patients
receiving chemotherapy have been published [10].
All patients in each study center who were hospitalized and underwent
HSCT between January 1, 2011 and October 30, 2011 were eligible for in-
clusion. A single case report form was used for each subject to record the
following data: demographic characteristics, type of HSCT and pre-
transplantation conditioning, IFD risk factors, clinical features suggestive of
IFD, results of mycological testing if available, antifungal prophylaxis and
treatment, and survival at discharge. Physicians diagnosed and treated cases
of IFD according to their usual practice, using their own judgment. In pa-
tients who received antifungal treatment (at investigator discretion), the
case report form was also used to record initial treatment strategy against
protocol deﬁnitions of prophylaxis and treatment scenarios (empirical,
administered to patients with immune deﬁciency, prolonged corticosteroid
use, persistent fever of unknown cause, or unresponsive to broad-spectrum
antibiotics for 7 days; pre-emptive, administered to patients with indirect
microbiological evidence of infection [antigen test]; or targeted, adminis-
tered to patients with proven IFD [11]), treatment adjustment, and treat-
ment course. IFD was categorized as proven, probable, or possible according
to European Organization for Research and Treatment of Cancer/Invasive
Fungal Infections Cooperative Group and the National Institute of Allergy
and Infectious Diseases Mycoses Study Group (EORTC/MSG) 2008 criteria
[12]. Patients were diagnosed as having suspected IFD if they had IFD risk
factors; were observed to have symptoms, radiological abnormalities, or
indirect microbiological evidence of fungal infection; and were treated
empirically with antifungal agents but could not be diagnosed with proven,
probable, or possible IFD according to EORTC/MSG 2008 criteria. Docu-
mentation continued until termination of antifungal treatment, completionof observation, or death. Patients were followed for 6 months  7 days after
the date of transplantation; follow-up was completed on April 30, 2012. In
all, 30 patients were lost to follow-up.
This study was conducted in accordance with the Declaration of Hel-
sinki, International Conference on Harmonisation Good Clinical Practice,
and nationally mandated ethical requirements. The study protocol and
informed consent document were reviewed and approved by the ethics
committee of Peking University People’s Hospital. All other participating
institutions obtained ethical approval separately before initiation of the
study. All study participants provided informed consent.
Data Analysis
Sample size calculation was based on the proportion of patients ex-
pected to develop IFD based on published data. Assuming an overall inci-
dence of IFD of 8% with a 5% margin of error [13,14] at least 707 patients
were required.
In accordance with common practice, and to maximize diagnostic ac-
curacy, incidence of IFD was calculated based on proven and probable cases
combined. Cumulative incidence was calculated as the incidence of proven
plus probable IFD for the ﬁrst 187 days after transplantation, divided by the
number of cases at risk. Unless stated otherwise, IFD data in this manuscript
refer to proven and probable cases combined. Data were grouped according
to transplantation type (autologous or allogeneic).
Statistics were primarily descriptive and were compared using analysis
of variance, Wilcoxon rank-sum test, or chi-squared test, as appropriate. Risk
factors for IFD were analyzed using univariate analysis followed by multi-
variate logistic regression. Each risk factor with a P value < .15 on univariate
analysis was examined further using multivariate logistic regression, in
which clinical signiﬁcance and interaction between variables were taken
into account. Overall survival status was estimated from the engraftment to
6 months using the Kaplan-Meier method and subgroups were compared
statistically using the log-rank test. Risk factors for death were analyzed by
univariate analysis. Each risk factor with a P value < .10 was included as a
covariate in multivariate analysis using the Cox proportional hazard
regression model. Factors with P  .05 in the ﬁnal analysis were considered
statistically signiﬁcant.
RESULTS
Patient Characteristics
A total of 1401 patients undergoing HSCT were enrolled
from 31 HSCT centers across China (n  10 at 7 centers; n ¼
10 to 50 at 16 centers; n¼ 51 to 100 at 7 centers; n> 100 at 1
center). Table 1 shows baseline patient demographic and
clinical characteristics at the time of admission for
transplantation.
In the overall population, the mean age was 31.1 years
(range, 1 to 66 years) and 252 patients (18%) were children
(age < 18 years). Over 90% of patients had profound neu-
tropenia with an absolute neutrophil count (ANC) < 500/
mm3 for a median of 14 days. Eastern Cooperative Oncology
Group scores indicated that most patients were able to un-
dertake routine activities of daily living with few limitations.
Three quarters of the patients (n ¼ 1053; 75.2%) received
allogeneic transplants and one quarter (n ¼ 348; 24.8%)
received autologous transplants. A total of 504 (47.9%) allo-
geneic HSCT patients developed graft-versus-host disease
(GVHD) within 6 months of transplantation (39.8% acute
GVHD [19.6% grade III or IV] and 13.8% chronic GVHD [71.7%
local lesions]). Median time from transplantation to onset of
acute and chronic GVHD was 23 and 135 days, respectively.
In the overall population, incidence of oral or intestinal
mucositis was 48.5% (679 of 1401), primarily grade 1 (40.9%)
or grade II (35.8%); 8.4% had grade IV severity. The median
time from transplantation to onset of inﬂammation was 6
days (interquartile range [IQR], 3 to 8).
Incidence of IFD and Associated Risk Factors
Incidence
In all, 374 patients were diagnosed with IFD: the in-
cidences of proven, probable, and possible IFD were 1.1% (16
of 1401), 6.6% (92 of 1401), and 19.0% (266 of 1401),
Table 1
Baseline Demographic and Clinical Characteristics of 1401 Patients Undergoing HSCT
Characteristic Overall Population (N ¼ 1401) Allogeneic HSCT (n ¼ 1053) Autologous HSCT (n ¼ 348)
Age, mean (SD), yr 31.1 (14.3) 29.0 (13.2) 37.7 (15.4)
Male 868 (62.0) 643 (61.1) 225 (64.7)
Underlying disease
Acute myeloid leukemia 451 (32.2) 376 (35.7) 75 (21.6)
Acute lymphocytic leukemia 327 (23.3) 310 (29.4) 17 (4.9)
Non-Hodgkin lymphoma 156 (11.1) 31 (2.9) 125 (35.9)
Chronic myeloid leukemia 127 (9.1) 126 (12.0) 1 (.3)
Aplastic anemia 83 (5.9) 82 (7.8) 1 (.3)
Myelodysplastic syndrome 81 (5.8) 80 (7.6) 1 (.3)
Multiple myeloma 75 (5.4) 3 (0.3) 72 (20.7)
Hodgkin’s disease 31 (2.2) 5 (0.5) 26 (7.5)
Unclassiﬁed acute leukemia 19 (1.4) 17 (1.6) 2 (0.6)
Solid tumor 12 (.9) 1 (.1) 11 (3.2)
Hereditary and metabolic disorders 9 (.6) 9 (.9) 0
Chronic lymphocytic leukemia 4 (.3) 4 (.4) 0
Acute promyelocytic leukemia 3 (.2) 0 3 (.9)
Others 23 (1.6) 9 (.9) 14 (4.0)
Transplantation type
Allogeneic 1053 (75.2) - -
HLA-matched related (sibling) 447 (42.5) 447 (42.5) -
Haploidentical 330 (31.3) 330 (31.3) -
Unrelated 275 (26.1) 275 (26.1) -
Autologous 348 (24.8) - -
Source of stem cells
Peripheral blood 920 (65.7) 589 (55.9) 331 (95.1)
Bone marrow þ peripheral stem cells 396 (28.3) 387 (36.8) 9 (2.6)
Bone marrow 46 (3.3) 40 (3.8) 6 (1.7)
Cord blood 21 (1.5) 19 (1.8) 2 (.6)
Other* 18 (1.3) 18 (1.7) 0
Conditioning regimen
Myeloablative 1201 (85.7) 936 (88.9) 265 (76.1)
Systemic radiotherapy 201 (14.4) 158 (15.0) 43 (12.4)
Previous IFD 126 (9.0%) 105 (10.0%) 19 (5.5%)
Concomitant disease
Cardiovascular disease 58 (4.1) 29 (2.8) 29 (8.3)
Diabetes 45 (3.2) 32 (3.0) 13 (3.7)
Viral hepatitis 45 (3.2) 35 (3.3) 10 (2.9)
Tuberculosis 24 (1.7) 19 (1.8) 5 (1.4)
Autoimmune diseases 11y (.8) 10 (.9) 1 (.3)
Endocrine and metabolic disease 7z (.5) 6 (.6) 1 (.3)
CMV infection 4 (.3) 4 (.4) 0
Respiratory disease 4x (.3) 1 (.1) 3 (.9)
CMV indicates cytomegalovirus.
Data are n (%) unless stated otherwise.
* Combined bone marrow and cord blood (n ¼ 3); bone marrow, peripheral stem cells, and cord blood (n ¼ 11); peripheral stem cells and cord blood (n ¼ 4).
y Psoriasis (n ¼ 6), rheumatoid arthritis (n ¼ 2), ankylosing spondylitis (n ¼ 3).
z Thyroid disorder (n ¼ 5), osteoporosis (n ¼ 1), hyperlipidemia (n ¼ 1).
x Asthma (n ¼ 3); chronic obstructive pulmonary disease (n ¼ 1).
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centers, ranging from 0 to 29% (IQR, 1.4 to 12.5), with a me-
dian of 6.7%. Of the 108 proven/probable cases, 14 developed
during the conditioning period before transplantation, 92
within 6 months afterwards, and 2 cases occurred more than
6 months (192 and 240 days) after transplantation. Two
patients who were diagnosed with proven or probable IFD
before admission and continued antifungal treatment during
hospitalization were excluded from incidence calculations
because their infections were caused by procedures unre-
lated to transplantation.
The incidences of proven and probable IFD after trans-
plantation in recipients of allogeneic or autologous trans-
plants were 8.9% (94 of 1053; 11 cases developed before
HSCT) and 4.0% (14 of 348; 3 cases developed before HSCT),
with a median time from transplantation to IFD of 45 days
(IQR, 16 to 93) and 14 days (IQR, 8 to 63), respectively.
The cumulative incidence of proven and probable
IFD increased rapidly within 1 month after transplanta
tion before leveling off (Figure 1). Six months after trans-
plantation, the cumulative incidence was 7.7% andsigniﬁcantly higher in allogeneic compared with autologous
HSCT patients (9.2% versus 3.5%, P¼ .001) and in thosewhose
stem cells were derived from cord blood rather than bone
marrow and peripheral blood (P ¼ .02 versus other sources).
The cumulative incidence in recipients of HLA-matched
related, haploidentical, and unrelated HSCT was 4.3%, 13.2%,
and 12.8%, respectively (Figure 1).
In the 108 patients with proven/probable IFD, 8 had evi-
dence of fungal infection in the blood and 81 had evidence in
the respiratory tract. Fungal species, identiﬁed in only 51 of
108 (47.2%) cases, were predominantly Aspergillus (36 of 51;
70.6%) and Candida (14 of 51; 27.5%). A single case ofMucor of
unspeciﬁed species was reported. The remaining 57 cases of
IFD were diagnosed without formal identiﬁcation of fungal
species, for example by beta-D-glucan test. Among the 14
probable IFD identiﬁed before transplantation, 5 were
Aspergillus, 4 were Candida, and 5 were unidentiﬁed. Species
identiﬁcation relied on the availability of microbio
logical testing in individual hospitals and was not a core
requirement of the study. These data should therefore be
interpreted with caution.
Figure 1. Cumulative incidence of invasive fungal disease (IFD) in recipients
of transplants from (A) different donor types and (B) different sources of
stem cell 187 days after hematopoietic stem cell transplantation (n ¼ 1387;
the 14 IFDs that occurred before transplantation were excluded from this
analysis).
Y. Sun et al. / Biol Blood Marrow Transplant 21 (2015) 1117e11261120Demographic characteristics of patients with proven and
probable IFD were similar to those of the overall trans-
plantation population.Risk Factors for Proven and Probable IFD
Risk factors for proven and probable IFD among alloge-
neic and autologous transplant recipients are presented in
Tables 2 and 3. Independent risk factors for proven and
probable IFD in allogeneic HSCT patients were prolonged,
profound neutropenia (ANC < 500/mm3 for >14 days: odds
ratio [OR], 3.37; 95% conﬁdence interval [CI], 1.87 to 6.07; P
< .01), diabetes (OR, 2.89; 95% CI, 1.10 to 7.57; P ¼ .03), an
HLA-matched unrelated donor (OR, 2.61; 95% CI, 1.33 to
5.15; P < .01), and use of CD25 monoclonal antibody (OR,
1.99; 95% CI, 1.01 to 3.91; P ¼ .05, borderline signiﬁcance); a
haploidentical donor was of borderline signiﬁcance (OR,
1.98; 95% CI, .98 to 4.03; P ¼ .06) (Table 2). Use of antifungal
prophylaxis showed an independent protective effect (OR,
.41; 95% CI, .22 to .76; P ¼ .01). Among recipients of autol-
ogous HSCT, previous proven and probable IFD was the only
clearly signiﬁcant risk factor (OR, 14.72; 95% CI, 2.76 to
78.40; P < .01), whereas prolonged, profound neutropenia
was of borderline signiﬁcance (OR, 3.78; 95% CI, 1.05 to
13.54; P ¼ .04) (Table 3).Antifungal Therapy
In all, 1175 (83.9%) patients were treated with antifungal
prophylaxis and 569 (40.6%) patients received antifungal
treatment; 514 (36.7%) were treated in the hospital.
IFD prophylaxis
In total, 1175 (83.9%) patients received primary (1071;
91.1%) or secondary (104; 8.9%) antifungal prophylaxis for a
median of 31 days (IQR, 19 to 46) during hospitalization; 204
(17.4%) continued prophylaxis after discharge. Among allo-
geneic HCST patients, 86.0% received prophylaxis (median
duration, 35 days; IQR, 20 to 52) compared with 77.3% of
autologous patients (median duration, 22 days; IQR, 14 to
32). The antifungal prophylaxis rate was also higher when
the source of stem cells was bone marrow and peripheral
blood (94.7%) and when patients were treated with mye-
loablation therapy (85.7% versus 73.0%) or antithymocyte
globulin (89.8% versus 78.9%). In all, 1016 (86.5%) patients
received prophylaxis before transplantation, for a median 10
days. The most widely used agents were triazoles (91.6%);
speciﬁcally, ﬂuconazole (61.4%), itraconazole (22.3%), and
voriconazole (19.4%). Prophylaxis was administered orally in
55.9% of patients, intravenously in 28.0%, and both routes (in
any order) in 16.1%.
Among patients who received antifungal prophylaxis, 431
of 1175 (36.7%) were later treated with antifungal therapy
because of clinical manifestations suggestive of possible IFD.
In total, 325 (75.4%) patients were switched to a different
antifungal agent from that used for prophylaxis. Of the pa-
tients treated with prophylaxis, 255 (21.7%) were ultimately
diagnosed as having IFD (218 [20.4%] and 37 [35.6%] re-
cipients of primary and secondary prophylaxis, respectively;
82 of 255 [32.2%] proven/probable IFD) based on clinical or
microbiological evidence.
Overall antifungal therapy
A total of 569 patients were started on therapeutic anti-
fungal treatment, 514 (36.7%) while in the hospital; 55 pa-
tients received antifungal agents after discharge only. The
analysis below is based only on patients treated in the
hospital, for whom the records are reliable. At the time
antifungal therapy was initiated, proven, probable, possible
and suspected IFD had been diagnosed in 8 (1.6%), 71 (13.8%),
172 (33.5%), and 263 (51.2%) patients, respectively (Table 4).
Median overall treatment duration in patients who started
and completed antifungal treatment while hospitalized was
27 days (IQR, 15 to 48) and 286 (59.1%) patients continued
treatment after leaving the hospital.
The most commonly used agents were triazoles (89.1%),
echinocandins (33.9%), and amphotericin B (13.4%). The
median time fromHSCT to initial treatment was 16 days (IQR,
4 to 33). A single antifungal agent was used for treatment in
294 (57.2%) patients; 174 (33.9%) patients required 2 agents
and 46 (8.9%) required 3 or more during the course of their
treatment.
Initial antifungal therapy during hospitalization
Of the 514 patients treated with antifungal agents while
in the hospital, the majority (483; 94.0%) received mono-
therapy initially; only 31 (6.0%) started on combination
therapy. The most commonly used antifungal agents for
initial treatment were triazoles (77.6%) or echinocandins
(21.0%). Individual antifungal agents used are shown in
Supplementary Table S1. Most patients (423; 82.3%) were
treated empirically; pre-emptive or targeted treatments
Table 2
Risk Factors for Proven/Probable IFD among Patients with Hematological Malignancy Receiving Allogeneic HSCT (n ¼ 1053)
Factor Univariate Analysis Multivariate Analysis
Patients with Proven/
Probable IFD (n/N)
Incidence of Proven/
Probable IFD (%)
Comparison
(P Value)
SE OR (95% CI) Comparison
(P Value)
Previous IFD
Yes 15/105 14.29 .05 .35 1.42 (.71-2.82) .32
No 79/948 8.33
Diabetes
Yes 7/32 21.88 .02 .49 2.89 (1.10-7.57) .03
No 87/1021 8.52
Transplantation type
HLA-matched related (sibling) 20/447 4.47 .0001
Haploidentical 42/330 12.73 .36 1.98 (.98-4.03) .06
HLA-matched unrelated 32/275 11.64 .35 2.61 (1.33-5.15) <.01
Source of stem cells
Bone marrow 1/40 2.50 .16
Bone marrow þ peripheral blood 40/387 10.34 1.06 3.03 (.38-24.33) .30
Cord blood 3/19 15.79 1.25 5.72 (.49-66.37) .16
Peripheral blood 47/589 7.98 1.06 3.03 (.38-24.31) .30
Prolonged, profound neutropenia
(ANC < 500/mm3 for >14 days)
Yes 19/443 4.29 <.001 .30 3.37 (1.87-6.07) <.01
No 75/610 12.30
GVHD*
cGVHD local 2/76 2.63 .03 .35 1.37 (.69-2.71) .36
cGVHD extensive 4/30 13.33
aGVHD I-II degree 26/288 9.03
aGVHD III-IV degree 12/73 16.44
Non-GVHD 45/549 8.20
Use of steroidsy
Yes 87/864 10.07 .004 .43 1.60 (.69-3.74) .28
No 7/188 3.72
Use of immunosuppressantsz
Yes, with CD25 monoclonal antibody 17/83 20.48 .002 .35 1.99 (1.01-3.91) .05
Yes, with others 77/963 8.00
No 0/7 0
EBV viremiax
Yes 13/77 16.88 .001 .36 1.46 (.72-2.96) .29
No 60/801 7.49
Untested 21/174 12.07
CMV viremiax
Yes 45/331 13.60 .001 .26 1.25 (.75-2.08) .39
No 46/684 6.73
Untested 3/37 8.11
Renal impairment
Yes 15/91 16.48 .019 .35 1.46 (.73-2.93) .28
No 79/961 8.22
Hepatic impairment
Yes 40/372 10.75 .142 .25 .97 (.60-1.57) .87
No 54/680 7.94
Decreased albumin
Yes 53/423 12.53 .001 .25 1.34 (.83-2.17) .23
No 41/629 6.52
Prophylaxis of IFD
Yes 73/906 8.06 .02 .32 .41 (.22-.76) .01
No 21/147 14.29
cGVHD indicates chronic graft-versus-host disease; aGVHD, acute graft-versus-host disease; EBV, Epstein-Barr virus.
Univariate analysis: bold type represents factors with P < .20 that were included in the subsequent multivariate model to identify independent risk factors for
IFD. Multivariate analysis: bold type indicates factors signiﬁcant at the 95% level.
* On multivariate analysis, OR is for cGVHD extensive/aGVHD III and IV degree versus cGVHD local/aGVHD I and II degree/non-GVHD.
y Including dexamethasone, methylprednisolone, prednisone, hydrocortisone.
z On multivariate analysis, OR is for CD25 monoclonal antibody versus other immunosuppressant or without immunosuppressant.
x On multivariate analysis, OR is for with EBV viremia versus without EBV viremia or untested/CMV viremia versus without CMV viremia or untested.
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The initial treatment was modiﬁed (including changes in
dosage form between oral and intravenous or change to
another antifungal agent) in 320 (62.3%) patients (once in
216 [67.5%] patients, twice in 55 [17.2%], and 3 times in 49
[15.3%]). The main reasons for treatment modiﬁcation were
standard sequential therapy (55.0%), inadequate efﬁcacy
(27.8%), poor tolerability (9.7%), and ﬁnancial considerations
(4.4%).Outcomes Including Mortality
During the study period, 188 patients died, resulting in an
overall mortality rate of 13.4% (188 of 1401); 35 deaths
(18.6%) were IFD related. In all, 62 patients died while in the
hospital and 126 were discharged while within 6 months
after discharge. Compared with the overall population, the
mortality rate was markedly higher in patients with proven
(5 of 16; 31.3%), probable (20 of 92; 21.7%), or possible (61 of
266; 22.9%) IFD and over 3 times higher after allogeneic (171
Table 3
Risk Factors for Proven/Probable IFD among Patients with Hematological Malignancy Receiving Autologous HSCT (n ¼ 348)
Risk Factors Univariate Analysis Multivariate Analysis
Patients with Proven/
Probable IFD (n/N)
Incidence of Proven/
Probable IFD (%)
Comparison
(P Value)
SE OR (95% CI) Comparison
(P Value)
Previous IFD
Yes 4/19 21.05 .01 .85 14.72 (2.76-78.40) <.01
No 10/329 3.04
Disease status before transplantation
Initial therapy/NR 4/24 16.67 .01 .80 3.78 (.78-18.27) .10
Others* 10/324 3.09
Prolonged, profound neutropenia
(ANC < 500/mm3 for >14 days)
Yes 7/57 12.28 .01 .65 3.78 (1.05-13.54) .04
No 7/291 2.75
Time to leukocyte engraftment > 14 days
Yes 5/63 7.94 .15
No 9/284 3.17
Oral or intestinal mucositis
Yes 10/144 6.94 .03 .70 1.69 (.43-6.63) .45
No 4/204 1.96
CMV viremiay
Yes 3/16 18.75 .04 .91 1.97 (.33-11.64) .45
No 9/270 3.33
Untested 2/62 3.23
Decreased albumin
Yes 8/90 8.89 .01 .73 1.93 (.66-11.53) .16
No 6/258 2.33
Parenteral nutrition
Yes 10/144 6.94 .03 .71 1.18 (.29-4.76) .71
No 4/204 1.96
NR indicates not reported.
Univariate analysis: bold type represents factors with P < .15 that were included in the subsequent multivariate model to identify independent risk factors for
IFD. Multivariate analysis: bold type indicates factors signiﬁcant at the 95% level.
* Others: includes complete response, partial response, relapse.
y On multivariate analysis, OR is for with EBV viremia versus without EBV viremia or untested/CMV viremia versus without CMV viremia or untested.
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HSCT. The mortality rate among patients treated for sus-
pected IFD despite failing to meet EORTC/MSG diagnostic
criteria (25 of 195; 12.8%) was somewhat higher than that
among patients who were not suspected of having IFD and,
therefore, not treated with antifungals (77 of 832; 9.3%).
Survival probabilities by HSCT type and by IFD status are
shown in Figure 2. Results for multifactorial Cox regression
analysis of overall survival in the whole study population
show that the risk of death was higher among patients with
renal dysfunction (hazard ratio [HR], 2.59), mucositis (HR,
1.86), IFD (HR, 1.79), and systemic radiotherapy conditioning
(HR, 1.77) than in patients without these factors (Table 5).
Patients who had stabilization of underlying disease before
HSCT were less likely to die than those who were in pro-
gression (HR, .41).Table 4
Antifungal Treatment andMortality among 514 Hospitalized Patients with Hematol
Initiated
Antifungal Agents
Triazoles* Alone
(n ¼ 252)
Amphoterici
Alone (n ¼ 8
IFD diagnosis level at initiation of therapy
Proven 3 (1.2) 0
Probable 17 (6.7) 3 (37.5)
Possible 84 (33.3) 4 (50.0)
Suspected 148 (58.7) 1 (12.5)
Death 33 (13.1) 0
Data are n (%).
* Fluconazole, itraconazole, voriconazole.
y Amphotericin B, liposomal amphotericin B.
z Caspofungin, micafunginThe mortality rates in hospitalized patients treated with
empirical, pre-emptive, or targeted antifungal therapy were
26 of 423 (6.1%), 13 of 70 (18.6%), and 2 of 21 (9.5%),
respectively (P ¼ .002). Mortality was highest among pa-
tients who required adjustment to their initial antifungal
regimen and was similar for patients treated with triazoles
and echinocandins (Table 4). No deaths were reported
among patients who received amphotericin B monotherapy,
although the number of patients in this group was too small
to draw any ﬁrm conclusions.
Among patients who developed IFD, mortality risk was
increased in patients with oral or intestinal mucositis (31.0%
versus 14.0% in thosewithout oral or intestinal mucositis; P¼
.04), those using a ventilator (100.0% versus 20.9%; P ¼ .01),
and in patients receiving parenteral nutrition (34.8% versus
14.5%; P ¼ .02). With the small numbers involved, no clearogical Malignancy Receiving HSCTat the Time Antifungal Therapy for IFDwas
n By
)
Echinocandinsz
Alone (n ¼ 34)
Two or More Antifungal
Agents (n ¼ 220)
Total (n ¼ 514)
0 5 (2.3) 8 (1.6)
2 (5.9) 49 (22.3) 71 (13.8)
10 (29.4) 74 (33.6) 172 (33.5)
22 (64.7) 92 (41.8) 263 (51.2)
5 (14.7) 60 (27.3) 98 (19.1)
Figure 2. Overall survival in (A) patients who received allogeneic hemato-
poietic stem cell transplantation (HSCT) or autologous HSCT; (B) patients with
proven/probable invasive fungal disease (IFD), possible IFD, suspected IFD and
receiving antifungal therapy, no suspected IFD and not receiving antifungal
therapy, or any IFD (proven, probable, or possible).
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or lower risk of mortality in these subgroups was observed.
Among the 18 deaths in patients with mucositis and IFD, 4
had Candida infection, 4 had Aspergillus, and 10 had IFD of
unidentiﬁed species. Similarly, of the 16 patients on paren-
teral nutrition who died with IFD, 3 had candidiasis, 3 had
Aspergillus infection, and 10 had unidentiﬁed IFD.
Of the patients diagnosedwith IFDwhile hospitalizedwho
were still alive at discharge, 82.5% (260 of 315) showedTable 5
Multifactorial Cox Regression Analysis for Overall Survival in the Whole Study Pop
Risk Factors Coefﬁcient SE
Age
20-40 yr versus <20 yr .01 .19
>40 yr versus <20 yr .15 .23
Renal dysfunction .95 .21
Hepatic impairment .13 .17
Diagnosed as IFD* .58 .16
Conditioning with systemic radiotherapy .57 .18
Type of transplantation
Autologous versus allogeneic HSCT .98 .61
Patients with mucositis .62 .17
Gender: male versus female .22 .16
Use of immunosuppressant .23 .64
Disease status before HSCTy
Stabilization versus progression .88 .16
Use of steroids .15 .20
Antifungal prophylaxis .07 .21
* Proven, probable, or possible IFD.
y Stabilized disease status included initial therapy, ﬁrst complete remission (CR1
phase, accelerated phase and aplastic anemia; progressed status included non-remis
CR4.clinical response or improvement (86.7% [196 of 226], 73.5%
[50 of 68], and 66.7% [14 of 21] of patients treated with
empirical, pre-emptive, and targeted antifungal therapy,
respectively).DISCUSSION
The CAESAR study is, to our knowledge, the largest pro-
spective observational study of patients at risk of IFD, in
China or elsewhere. In the present analysis of adults and
children at risk of IFD due to HSCT, the proven/probable IFD
incidence rate was 7.7% overall, comprising 1.1% proven IFD
and 6.6% probable IFD. Compared with autologous HSCT
patients, allogeneic transplant recipients had a higher inci-
dence of proven/probable IFD overall (9.0% versus 4.3%) and
at 6 months (9.0% versus 3.5%). However, it is worth noting
that autologous HSCT patients have less frequent follow-up
visits (usually monthly) than allogeneic HSCT patients did
(weekly), which might result in a lower frequency of diag-
nosed IFDs. A small number of patients (14 of 1401; 1.0%)
were identiﬁed as having probable IFD before trans-
plantation, reﬂecting the risk of developing IFD during pre-
treatment conditioning; 13 of these patients received
myeloablative conditioning and 8 (57%) had suffered IFDs
previously, a much higher proportion than the overall study
population, perhaps increasing their risk for early IFD.
Importantly, the cumulative incidence of proven/probable
IFD increased particularly rapidly during the ﬁrst month after
transplantation, suggesting that this is a high-risk period
during which health care providers should pay particularly
close attention to signs of emerging IFD in HSCT patients. It is
also worth noting that the median time between trans-
plantation and IFD tended to be shorter in autologous HSCT
patients (median, 14 days versus 45 days in allogeneic HSCT).
Comparing outcomes between studies of IFD is compli-
cated by varied deﬁnitions of IFD, as well as inclusion criteria
and diagnostic stratiﬁcations (proven, probable, or possible
IFD), which differ by country and by treatment center.
Furthermore, many studies recruit mixed populations of
high-risk patients, including transplant recipients and
chemotherapy patients, and do not distinguish between
them in their analyses. These issues aside, the incidence rates
identiﬁed in the present study are higher than those in the
large Transplant-Associated Infection Surveillance Networkulation (N ¼ 1401)
Walds P Value HR 95% CI of HR
.01 .94 1.01 .70-1.47
.44 .50 .86 .54-1.35
21.57 <.01 2.59 1.73-3.88
.60 .44 1.14 .82-1.58
12.60 <.01 1.79 1.30-2.48
10.38 <.01 1.77 1.25-2.49
2.59 .11 .38 .11-1.24
13.85 <.01 1.86 1.34-2.58
1.88 .17 1.25 .91-1.72
.13 .72 1.26 .36-4.37
31.13 <.01 .41 .30-.56
.56 .46 .86 .58-1.27
.11 .74 .93 .62-1.40
), second complete remission (CR2), near complete remission (nCR), chronic
sion (NR), partial remission (PR), relapse and third complete remission (CR3)
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States tertiary care centers, in which 1-year overall incidence
of proven/probable IFD was 3.4% (range, .9% to 13.2%), lower
among autologous transplant recipients (1.2%) and higher
after allogeneic HSCT (5.8% to 8.1% depending on donor type)
[2]. The Transplant-Associated Infection Surveillance
Network data are similar to those from the large retrospec-
tive SEIFEM study in > 3000 patients in Italy (overall inci-
dence 3.7%) [4] and from some small single-center studies
[15]. However, incidence of IFD has often been considerably
higher than this in single-center studies, particularly among
allogeneic transplant recipients, in whom rates are often
13% [16-20]. For example, single-center studies in alloge-
neic HSCT patients in China [17] and Austria [18] reported
cumulative incidence rates of 13%, whereas studies in Italy
[19] and Canada [20] both described invasive aspergillosis
rates of 15% in allogeneic HSCT patients despite different
donor populations and conditioning regimens. Similarly, in
the present study, a wide range of incidence data (0 to 29%)
was reported by different centers, suggesting that differences
in epidemiological outcomes may reﬂect different study
designs; patient populations with different baseline clinical
characteristics and risk proﬁles; and transplantation, condi-
tioning regimen, and treatment practices that vary by center.
The lack of standardization of procedures for detecting and
diagnosing IFD in this observational study might also
contribute to the wide range of results. Exploratory analyses
of our data among subgroups of centers categorized as hav-
ing a low, intermediate, high, or very high incidence of
proven/probable IFD suggest that those in the high incidence
category are more likely to have patients with more severe
underlying disease, with a higher proportion of patients
having progressive disease than in the other categories
(Supplementary Table S2). Conversely, centers with the
lowest IFD incidence had the highest proportion of child-
hood malignancies. However, there was an imbalance in the
numbers of patients in each of these categories and insufﬁ-
cient data were collected to make a full assessment of the
relative risk status of patient populations across centers.
Further and more comprehensive study incorporating addi-
tional measures such as performance status and environ-
mental factors will help to identify centers that serve a
higher risk patient population and to inform optimum
practices for minimizing the incidence of IFD in these
centers.
There are several possible reasons why the CAESAR study
may have identiﬁed a somewhat higher incidence of IFD than
did studies in the United States and some parts of Europe.
These include the relatively high rate of haploidentical
transplantation (40%) and insufﬁcient use of prophylaxis in
these patients (10% of allogeneic HSCT patients did not
receive prophylaxis), as well as in other high-risk groups
such as allogeneic HSCT patients inwhom lack of prophylaxis
was associated with an increased incidence of IFD (15%
versus 8%). Furthermore, ﬂuconazole, which has suboptimal
efﬁcacy compared with newer agents such as posaconazole
that were unavailable during the study period, was used
extensively for prophylaxis (61%) and for a shorter duration
than recommended (median, 31 days versus 75 days after
allogeneic HSCTor until neutrophil recovery after autologous
HSCT, as recommended by the National Comprehensive
Cancer Network [21]).
In this study, risk factors for IFD in patients receiving
allogeneic HSCT included diabetes, an HLA-matched unre-
lated donor, neutropenia with ANC < 500/mm3 for>14 days,and use of immunosuppressants; antifungal prophylaxis was
independently protective. Among allogeneic transplantation
patients, previous IFD and prolonged, profound neutropenia
were statistically signiﬁcant risk factors for IFD. Encourag-
ingly, the majority of patients (84%) received antifungal
prophylaxis (77% in autologous HSCT, 86% in allogeneic
HSCT) although, as noted above, some high-risk patients
were not given prophylaxis despite guidelines. promoting
prophylaxis. As 20.8% of patients treated with prophylaxis in
the present study went on to develop IFD, there remains an
unmet need for education about appropriate timing and
choice of antifungals for prophylaxis in China. In both
CAESAR analyses [10], the most commonly prescribed pro-
phylactic agent was ﬂuconazole, which may be less effective
than itraconazole [22] and posaconazole [23], and this may
represent a speciﬁc educational opportunity.
Antifungal therapy was initiated in 36.8% of hospitalized
patients for a median of 27 days, and triazoles were used in
89.1% of cases. The majority of patients (82%) were treated
empirically and only 4.5% of patients received targeted
antifungal therapy. These treatment strategies are broadly in
line with national guidelines in China [24], and preferential
use of empirical rather than pre-emptive treatment is sup-
ported by guidelines from other world regions [7,25].
In this study, mortality among patients who developed
IFD (w25%) was almost double that in the overall population
of HSCT patients (13.4%), and regression analysis conﬁrmed
that IFD is a signiﬁcant independent risk factor for death,
highlighting the grave prognosis of IFD and need for timely
diagnosis and prompt treatment. Allogeneic HSCT patients
had a considerably greater mortality risk than autologous
transplantation patients, as is widely documented and often
attributed to greater rates of invasive aspergillosis infection
[4,20,26]. Nonetheless, it is heartening to note the high
proportion (82.6%) of patients who achieved distinct clinical
improvement or complete response on discharge from the
hospital, and it is instructive that the highest improvement
rates were in those treated empirically (86.7% versus 73.5%
pre-emptive and 69.6% targeted). Importantly, patients
treated empirically had a signiﬁcantly lower mortality rate
(6.1%) than those treated pre-emptively (18.6%) or with tar-
geted antifungal therapy (8.7%).
The low rate of proven/probable IFD, compared with
possible IFD, in the present study suggests the need to
improve diagnostic techniques to treat IFD as early and
accurately as possible. As demonstrated in the previously
published CAESAR study in patients receiving chemotherapy
[10], microbiological and antigen testing are not widely used
in China because of the prohibitive cost and limited avail-
ability, and diagnostic testing often falls short of recom-
mendations [27]. First-line antifungal treatment was
modiﬁed in 62% of patients and in 28%, this was because of
suboptimal efﬁcacy, suggesting a need to improve physician
awareness of resistance patterns and appropriate ﬁrst-line
antifungal agents.
Limitations of this study include its observational nature
and relatively short duration; longer follow-up would have
allowed more comprehensive analysis of patients who
developed IFD after discharge. In the analysis of mortality by
antifungal therapy, the uncontrolled study designmeans that
no ﬁrm conclusions can be drawn regarding the relative ef-
fect of different treatments. The fact that overall treatment
duration was not recorded in patients who were still taking
antifungal treatment after discharge from the hospital
limited data analysis further. The study design only allowed
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of IFD could not be documented. Procedures for diagnosis,
prophylaxis, and treatment of IFD were not prespeciﬁed in
the protocol but were performed according to usual practice.
Based on recommendations from local clinical guidelines
[11], this would be expected to involve IFD screening by
beta-D-glucan test once a week and a computed tomography
scan performed once at 4 to 8 weeks during the 100 days
after transplantation; however, in some centers diagnostic
procedures were conducted only among patients with sus-
pected clinical signs or symptoms of IFD. The observational
design also meant that diagnosis of speciﬁc infections,
although guided by EORTC/MSG 2008 criteria, was limited to
the data collected according to local hospitals’ usual practice;
no mandatory requirement for diagnostic microbiological
testing or use of a centralized laboratory to validate the re-
sults was speciﬁed. Therefore, where other studies have
shown differences between Candida and Aspergillus in-
fections with respect to incidence, risk factors, and rela-
tionship to speciﬁc antifungal prophylaxis [2,3,28], such
analyses were beyond the scope of our study and will be
explored in future evaluations.
In summary, current management of IFD among patients
receiving HSCT for hematological malignancy in China is
broadly in line with recommended practice but there re-
mains room for improvement in the uptake of accurate, cost-
effective, diagnostic methods, and selection and timing of
prophylactic antifungals. The extensive use of empirical
antifungal treatment is encouraging. Health care providers
should remain alert to the increased risk of IFD and associ-
ated mortality in allogeneic HSCT recipients and to the
ongoing risk of IFD even after patients are discharged from
the hospital.
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